• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血小板活化因子降解性乙酰水解酶在人血浆中优先与致密低密度脂蛋白和VHDL-1相关。催化特性及其与单核细胞衍生酶的关系。

PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

作者信息

Tselepis A D, Dentan C, Karabina S A, Chapman M J, Ninio E

机构信息

Department of Chemistry, University of Ioannina, Greece.

出版信息

Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1764-73. doi: 10.1161/01.atv.15.10.1764.

DOI:10.1161/01.atv.15.10.1764
PMID:7583554
Abstract

In human plasma, platelet activating factor (PAF)-degrading acetylhydrolase (acetylhydrolase) is principally transported in association with LDLs and HDLs; this enzyme hydrolyzes PAF and short-chain forms of oxidized phosphatidylcholine, transforming them into lyso-PAF and lysophosphatidylcholine, respectively. We have examined the distribution, catalytic characteristics, and transfer of acetylhydrolase activity among plasma lipoprotein subspecies separated by isopycnic density gradient ultracentrifugation; the possibility that the plasma enzyme may be partially derived from adherent monocytes has also been evaluated. In normolipidemic subjects with Lp(a) levels < 0.1 mg/mL, acetylhydrolase was associated preferentially with small, dense LDL particles (LDL-5; d = 1.050 to 1.063 g/mL) and with the very-high-density lipoprotein-1 subfraction (VHDL-1; d = 1.156 to 1.179 g/mL), representing 23.9 +/- 1.7% and 20.6 +/- 3.2%, respectively, of total plasma activity. The apparent Km values for PAF of the enzyme associated with such lipoproteins were 89.7 +/- 23.4 and 34.8 +/- 4.5 mumol/L for LDL-5 and VHDL-1, respectively: indeed, the Km value for LDL-5 was some 10-fold higher than that of the light LDL-1, LDL-2, and LDL-3 subspecies, whereas the Km of VHDL-1 was some twofold greater than those of the HDL-2 and HDL-3 subspecies. Furthermore, when expressed on the basis of unit plasma volume, the Vmax of the acetylhydrolase associated with LDL-5 was some 150-fold greater than that in LDL-1 (d = 1.019 to 1.023 g/mL). No significant differences in the pH dependence of enzyme activity or in sensitivity to protease inactivation, sulfydryl reagents, the serine protease inhibitor Pefabloc, or the PAF antagonist CV 3988 could be detected between apo B-containing and apo A-I-containing lipoprotein particle subspecies. Incubation of LDL-1 (Km = 8.4 +/- 2.6 mumol/L) and LDL-2 (d = 1.023 to 1.029 g/mL; Km = 8.4 +/- 3.3 mumol/L) subspecies with LDL-5, in which acetylhydrolase had been inactivated by pretreatment with Pefabloc, demonstrated preferential transfer of acetylhydrolase to LDL-5. Acetylhydrolase transferred to LDL-5 from the light LDL subspecies exhibited a Km of 9.4 +/- 2.2 mumol/L, a value characteristic of the particle donors. Finally, acetylhydrolase (Km = 23.4 +/- 7.6 mumol/L) released by adherent human monocytes in culture was found to bind preferentially to small, dense LDL subspecies upon incubation of Pefabloc-inactivated plasma with monocyte supernatant.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

在人血浆中,血小板活化因子(PAF)降解乙酰水解酶(乙酰水解酶)主要与低密度脂蛋白(LDL)和高密度脂蛋白(HDL)结合运输;该酶水解PAF和短链形式的氧化磷脂酰胆碱,分别将它们转化为溶血PAF和溶血磷脂酰胆碱。我们通过等密度梯度超速离心法研究了血浆脂蛋白亚类中乙酰水解酶活性的分布、催化特性和转移情况;还评估了血浆酶可能部分来源于黏附单核细胞的可能性。在Lp(a)水平<0.1 mg/mL的血脂正常受试者中,乙酰水解酶优先与小而密的LDL颗粒(LDL-5;d = 1.050至1.063 g/mL)和极高密度脂蛋白-1亚组分(VHDL-1;d = 1.156至1.179 g/mL)结合,分别占血浆总活性的23.9±1.7%和20.6±3.2%。与这些脂蛋白结合的酶对PAF的表观Km值,LDL-5为89.7±23.4 μmol/L,VHDL-1为34.8±4.5 μmol/L:实际上,LDL-5的Km值比轻LDL-1、LDL-2和LDL-3亚类约高10倍,而VHDL-1的Km值比HDL-2和HDL-3亚类约高2倍。此外,以单位血浆体积表示时,与LDL-5结合的乙酰水解酶的Vmax比LDL-1(d = 1.019至1.023 g/mL)中的约高150倍。在含载脂蛋白B和含载脂蛋白A-I的脂蛋白颗粒亚类之间,未检测到酶活性的pH依赖性或对蛋白酶失活、巯基试剂、丝氨酸蛋白酶抑制剂苯甲磺酰氟或PAF拮抗剂CV 3988敏感性的显著差异。用苯甲磺酰氟预处理使乙酰水解酶失活的LDL-5与LDL-1(Km = 8.4±2.6 μmol/L)和LDL-2(d = 1.023至1.029 g/mL;Km = 8.4±3.3 μmol/L)亚类孵育,结果表明乙酰水解酶优先转移至LDL-5。从轻LDL亚类转移至LDL-5的乙酰水解酶的Km为9.4±2.2 μmol/L,这是颗粒供体的特征值。最后,在苯甲磺酰氟失活的血浆与单核细胞上清液孵育后发现,培养的黏附人单核细胞释放的乙酰水解酶(Km = 23.4±7.6 μmol/L)优先与小而密的LDL亚类结合。(摘要截短于400字)

相似文献

1
PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.血小板活化因子降解性乙酰水解酶在人血浆中优先与致密低密度脂蛋白和VHDL-1相关。催化特性及其与单核细胞衍生酶的关系。
Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1764-73. doi: 10.1161/01.atv.15.10.1764.
2
PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.体外铜离子诱导氧化修饰前后脂蛋白(a)的血小板活化因子乙酰水解酶活性
Atherosclerosis. 1996 Aug 23;125(1):121-34. doi: 10.1016/0021-9150(96)05872-8.
3
Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.人血浆低密度脂蛋白中血小板活化因子乙酰水解酶的可解离和不可解离形式:对低密度脂蛋白氧化易感性的影响
Biochim Biophys Acta. 1999 Jan 29;1437(1):23-36. doi: 10.1016/s0005-2760(98)00177-5.
4
Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).组织因子途径抑制剂在人血浆中的抗凝活性优先与低密度脂蛋白和高密度脂蛋白的致密亚类以及脂蛋白(a)相关。
Arterioscler Thromb. 1993 Jul;13(7):1066-75. doi: 10.1161/01.atv.13.7.1066.
5
Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL.铜催化氧化介导人低密度脂蛋白亚类中血小板活化因子(PAF)的形成。PAF乙酰水解酶在致密低密度脂蛋白中的保护作用。
Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3505-12. doi: 10.1161/01.atv.17.12.3505.
6
PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation.血浆低密度脂蛋白中血小板活化因子-乙酰水解酶可被铜介导及细胞介导的氧化作用所灭活。
Arterioscler Thromb. 1994 Mar;14(3):353-60. doi: 10.1161/01.atv.14.3.353.
7
Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.人血浆血小板活化因子乙酰水解酶。与脂蛋白颗粒的关联及在血小板活化因子降解中的作用。
J Biol Chem. 1987 Mar 25;262(9):4215-22.
8
Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.脂蛋白改变人血浆中血小板活化因子乙酰水解酶的催化行为。
Proc Natl Acad Sci U S A. 1989 Apr;86(7):2393-7. doi: 10.1073/pnas.86.7.2393.
9
Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.在杂合子家族性高胆固醇血症患者中,低密度脂蛋白亚组分中血小板活化因子乙酰水解酶活性增加,导致氧化过程中溶血磷脂酰胆碱生成增强。
Eur J Clin Invest. 1997 Jul;27(7):595-602. doi: 10.1046/j.1365-2362.1997.1570706.x.
10
Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase.苯磺酰氟,4-[2-氨乙基]苯磺酰氟,是一种新型、高效、无毒且不可逆的血小板活化因子降解乙酰水解酶抑制剂。
Biochim Biophys Acta. 1996 Feb 16;1299(3):353-7. doi: 10.1016/0005-2760(95)00226-x.

引用本文的文献

1
Can Electronegative LDL Act as a Multienzymatic Complex?负电性 LDL 可否充当多酶复合物?
Int J Mol Sci. 2023 Apr 11;24(8):7074. doi: 10.3390/ijms24087074.
2
HDL and Oxidation.高密度脂蛋白与氧化
Adv Exp Med Biol. 2022;1377:63-77. doi: 10.1007/978-981-19-1592-5_5.
3
Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients.早发性卵巢功能不全患者亚临床动脉粥样硬化中脂蛋白相关磷脂酶A2及炎症标志物的预测
Acta Cardiol Sin. 2021 Jan;37(1):30-37. doi: 10.6515/ACS.202101_37(1).20200730A.
4
A Standard Lipid Panel Is Insufficient for the Care of a Patient on a High-Fat, Low-Carbohydrate Ketogenic Diet.标准血脂检查对于高脂低碳水化合物生酮饮食患者的护理是不够的。
Front Med (Lausanne). 2020 Apr 15;7:97. doi: 10.3389/fmed.2020.00097. eCollection 2020.
5
LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL.载脂蛋白 B 致动脉粥样硬化性血脂异常的 LDL 亚类脂质组学:他汀类药物治疗对生物活性脂质和致密 LDL 的影响。
J Lipid Res. 2020 Jun;61(6):911-932. doi: 10.1194/jlr.P119000543. Epub 2020 Apr 15.
6
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.低密度脂蛋白导致动脉粥样硬化性心血管疾病:病理生理学、遗传学及治疗学见解:欧洲动脉粥样硬化学会共识小组的共识声明
Eur Heart J. 2020 Jun 21;41(24):2313-2330. doi: 10.1093/eurheartj/ehz962.
7
Pleiotropic effects of apolipoprotein A-Ⅱ on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis.载脂蛋白A-Ⅱ对高密度脂蛋白功能、脂肪组织代谢活性和血浆葡萄糖稳态的多效性作用。
J Biomed Res. 2019 Jul 26;0(0):1-13. doi: 10.7555/JBR.33.20190048.
8
Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?磷脂酶A2是心血管疾病中的一种炎症预测指标:在证明因果关系方面是否有很大空间?
Curr Cardiol Rev. 2020;16(1):3-10. doi: 10.2174/1573403X15666190531111932.
9
Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes.2 型糖尿病患者脂蛋白亚类中对氧磷酶 1(PON-1)和脂蛋白相关磷脂酶 A2(Lp-PLA2)的分布。
Oxid Med Cell Longev. 2018 Nov 5;2018:1752940. doi: 10.1155/2018/1752940. eCollection 2018.
10
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.选择性血栓抽吸对高血栓负荷的ST段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗时血清脂蛋白相关磷脂酶A2的影响
Acta Cardiol Sin. 2018 May;34(3):233-241. doi: 10.6515/ACS.201805_34(3).20170227A.